Vuppalanchi Raj, Are Vijay, Telford Alison, Young Liam, Mouchti Sofia, Ferreira Carlos, Kettler Carla, Gromski Mark, Akisik Fatih, Chalasani Naga
Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Perspectum Ltd., Oxford, UK.
JHEP Rep. 2023 Jun 29;5(10):100834. doi: 10.1016/j.jhepr.2023.100834. eCollection 2023 Oct.
BACKGROUND & AIMS: Magnetic resonance cholangiopancreatography (MRCP) for evaluation of biliary disease currently relies on subjective assessment with limited prognostic value because of the lack of quantitative metrics. Artificial intelligence-enabled quantitative MRCP (MRCP+) is a novel technique that segments biliary anatomy and provides quantitative biliary tree metrics. This study investigated the utility of MRCP+ as a prognostic tool for the prediction of clinical outcomes in primary sclerosing cholangitis (PSC).
MRCP images of patients with PSC were post-processed using MRCP+ software. The duration between the MRCP and clinical event (liver transplantation or death) was calculated. Survival analysis and stepwise Cox regression were performed to investigate the optimal combination of MRCP+ metrics for the prediction of clinical outcomes. The resulting risk score was validated in a separate validation cohort and compared with an existing prognostic score (Mayo risk score).
In this retrospective study, 102 patients were included in a training cohort and a separate 50 patients formed a validation cohort. Between the two cohorts, 34 patients developed clinical outcomes over a median duration of 3 years (23 liver transplantations and 11 deaths). The proportion of bile ducts with diameter 3-5 mm, total bilirubin, and aspartate aminotransferase were independently associated with transplant-free survival. Combined as a risk score, the overall discriminative performance of the MRCP+ risk score (M+BA) was excellent; area under the receiver operator curve 0.86 (95% CI: 0.77, 0.95) at predicting clinical outcomes in the validation cohort with a hazard ratio 5.8 (95% CI: 1.5, 22.1). This was superior to the Mayo risk score.
A composite score combining MRCP+ with total bilirubin and aspartate aminotransferase (M+BA) identified PSC patients at high risk of liver transplantation or death. Prospective studies are warranted to evaluate the clinical utility of this novel prognostic tool.
Primary sclerosis cholangitis (PSC) is a disease of the biliary tree where inflammation and fibrosis cause areas of narrowing (strictures) and expansion (dilatations) within the biliary ducts leading to liver failure and/or cancer (cholangiocarcinoma). In this study, we demonstrate that quantitative assessment of the biliary tree can better identify patients with PSC who are at high risk of either death or liver transplantation than a current blood-based risk score (Mayo risk score).
目前用于评估胆道疾病的磁共振胰胆管造影(MRCP)依赖主观评估,由于缺乏定量指标,其预后价值有限。基于人工智能的定量MRCP(MRCP+)是一种可对胆道解剖结构进行分割并提供胆道树定量指标的新技术。本研究探讨了MRCP+作为预测原发性硬化性胆管炎(PSC)临床结局的预后工具的效用。
使用MRCP+软件对PSC患者的MRCP图像进行后处理。计算MRCP检查与临床事件(肝移植或死亡)之间的时间间隔。进行生存分析和逐步Cox回归,以研究用于预测临床结局的MRCP+指标的最佳组合。在一个单独的验证队列中对所得风险评分进行验证,并与现有的预后评分(梅奥风险评分)进行比较。
在这项回顾性研究中,102例患者被纳入训练队列,另外50例患者组成验证队列。在这两个队列中,34例患者在中位时间3年内出现了临床结局(23例肝移植和11例死亡)。直径为3 - 5毫米的胆管比例、总胆红素和天冬氨酸转氨酶与无移植生存独立相关。作为一个风险评分综合起来,MRCP+风险评分(M+BA)的总体判别性能极佳;在验证队列中预测临床结局时,受试者操作特征曲线下面积为0.86(95%CI:0.77,0.95),危险比为5.8(95%CI:1.5,22.1)。这优于梅奥风险评分。
将MRCP+与总胆红素和天冬氨酸转氨酶相结合的综合评分(M+BA)可识别出肝移植或死亡风险高的PSC患者。有必要进行前瞻性研究以评估这种新型预后工具的临床效用。
原发性硬化性胆管炎(PSC)是一种胆道疾病,炎症和纤维化会导致胆管内出现狭窄和扩张区域,进而导致肝衰竭和/或癌症(胆管癌)。在本研究中,我们证明,与目前基于血液的风险评分(梅奥风险评分)相比,对胆道树进行定量评估能够更好地识别出有死亡或肝移植高风险的PSC患者。